Oxford Immunotec Limited: Study Results Show Switching from the Tuberculin Skin Test (TST) to an Interferon Gamma Release Assay (IGRA) can Improve Healthcare Worker Test Adherence at a Lower Cost  
6/27/2011 12:44:19 PM

OXFORD, England & MARLBOROUGH, Mass.--(BUSINESS WIRE)--The interim findings of the SWITCH study, “Screening healthcare Workers with IGRA vs. TST: Impact on Costs and adHerence to testing”, were presented today at the Association of Professionals in Infection Control and Epidemiology (APIC) annual meeting by Dr. Edward Bernacki, M.D. MPH, Executive Director, Health, Safety and Environment, The Johns Hopkins Health System and University, and Director, Division of Occupational Medicine, Johns Hopkins University, School of Medicine, a principal investigator of the study. The study compared costs and adherence to testing when healthcare workers were screened for tuberculosis (TB) using the tuberculin skin test (TST) or an Interferon Gamma Release Assay (IGRA).